V-LAP (811765)

  https://cordis.europa.eu/project/id/811765

  Horizon 2020 (2014-2020)

  A revolutionary direct, daily heart monitoring platform for long-term tailored treatment of Heart Disease patients.

  SME instrument (EIC-SMEInst-2018-2020)

  pharmaceutical drugs  ·  diabetes  ·  cardiology  ·  implants  ·  anaesthesiology

  2018-04-01 Start Date (YY-MM-DD)

  2020-03-31 End Date (YY-MM-DD)

  € 2,621,146 Total Cost

  Description

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed through a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes.

  Complicit Organisations

1 Israeli organisation participates in V-LAP.